| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Eur J Cardiothorac Surg 2000;18:143-146
© 2000 Elsevier Science NL
Department of Thoracic Surgery, Royal Brompton Hospital, Sydney Street, London SW3 6NP, London, UK
Received 12 November 1999; received in revised form 22 February 2000; accepted 22 February 2000.
Corresponding author. Tel.:+44-171-351-8559; fax: +44-171-351-8560
e-mail: p.goldstraw{at}rbh.nthames.nhs.uk
Objective: Over the last 15 years we have managed patients with malignant pleural effusion, using a single procedure with thoracoscopy and talc pleurodesis or shunt as appropriate. Talc pleurodesis remains our primary treatment option but in those patient shown to have the ‘trapped lung syndrome’, in whom pleurodesis would fail, we have been using a pleuroperitoneal shunt. Methods: This retrospective review was undertaken to evaluate the mortality and morbidity of pleuroperitoneal shunts in the management of malignant pleural effusions and to assess their long-term results. Three hundred and sixty patients were treated for malignant effusions during the period 1983–1998, 160 (44.4%) of whom had a pleuroperitoneal shunt inserted. There were no intraoperative deaths and the hospital mortality was three patients (1.87%). Follow up was available for 88.1% of patients. The median survival of all malignant cases was 7.7 months (range 1–72 months). Mesothelioma patients survived somewhat longer with a median survival of 10.1 months. Results: Shunt complication occurred in 21 patients (14.8%). Twelve patients developed shunt occlusion, requiring revision in five and replacement in seven. The shunt was removed in eight patients due to skin erosion in one patient and infection in seven patients. The distal limb of shunt was broken in one patient and the shunt was replaced. One patient developed malignant seeding along the chest wall at the site of shunt insertion but there were no incidences of peritoneal deposits. Effective palliation was achieved in 95% of patients. Conclusions: Pleuroperitoneal shunt insertion provides effective and safe palliation for malignant pleural effusion when associated with the ‘trapped lung syndrome’. There are however complications which require revision or shunt removal. There is no evidence that peritoneal deposits result from pleuroperitoneal shunting.
Key Words: Pleuro-peritoneal shunts • Malignant • Pleural effusion
This article has been cited by other articles:
|
|
 |
|
  R. A Qureshi, S. L Collinson, R. J Powell, P. O Froeschle, and R. G Berrisford Management of Malignant Pleural Effusion Associated with Trapped Lung Syndrome Asian Cardiovasc Thorac Ann, April 1, 2008; 16(2): 120 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. H. Warren, R. Kalimi, L. M. Khodadadian, and A. W. Kim Management of Malignant Pleural Effusions Using the Pleurx Catheter Ann. Thorac. Surg., March 1, 2008; 85(3): 1049 - 1055. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. H. Warren, A. W. Kim, and M. J. Liptay Identification of clinical factors predicting Pleurx (R) catheter removal in patients treated for malignant pleural effusion Eur. J. Cardiothorac. Surg., January 1, 2008; 33(1): 89 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 British Thoracic Society Standards of Care Committ BTS statement on malignant mesothelioma in the UK, 2007 Thorax, November 1, 2007; 62(Suppl_2): ii1 - ii19. [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Kvale, P. A. Selecky, and U. B. S. Prakash Palliative Care in Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 368S - 403S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Pilling, A. G. Nicholson, C. Harmer, and P. Goldstraw Prolonged Survival Due to Spontaneous Regression and Surgical Excision of Malignant Mesothelioma Ann. Thorac. Surg., January 1, 2007; 83(1): 314 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Rodriguez-Panadero, J. P. Janssen, and P. Astoul Thoracoscopy: general overview and place in the diagnosis and management of pleural effusion. Eur. Respir. J., August 1, 2006; 28(2): 409 - 422. [Full Text] [PDF]
|
|
|
|
|
|
C. Tan, A. Sedrakyan, J. Browne, S. Swift, and T. Treasure The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur. J. Cardiothorac. Surg., May 1, 2006; 29(5): 829 - 838. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Migliore Efficacy and safety of single-trocar technique for minimally invasive surgery of the chest in the treatment of noncomplex pleural disease J. Thorac. Cardiovasc. Surg., November 1, 2003; 126(5): 1618 - 1623. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Parker and E Neville Lung cancer * 8: Management of malignant mesothelioma Thorax, September 1, 2003; 58(9): 809 - 813. [Full Text] [PDF]
|
|
|
|
|
|
G. Cardillo, F. Facciolo, L. Carbone, M. Regal, F. Corzani, A. Ricci, M. Di Martino, and M. Martelli Long-term follow-up of video-assisted talc pleurodesis in malignant recurrent pleural effusions Eur. J. Cardiothorac. Surg., February 1, 2002; 21(2): 302 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.E. Martin-Ucar, J.G. Edwards, A. Rengajaran, S. Muller, and D.A. Waller Palliative surgical debulking in malignant mesothelioma : Predictors of survival and symptom control Eur. J. Cardiothorac. Surg., December 1, 2001; 20(6): 1117 - 1121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Sawabata, H. Maeda, M. Ohta, and M. Hayakawa Operable Non-small Cell Lung Cancer Diagnosed by Transpleural Techniques : Do They Affect Relapse and Prognosis? Chest, November 1, 2001; 120(5): 1595 - 1598. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
